{"id":"NCT04332991","sponsor":"Massachusetts General Hospital","briefTitle":"Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease","officialTitle":"Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-04-02","primaryCompletion":"2020-06-19","completion":"2020-07-23","firstPosted":"2020-04-03","resultsPosted":"2021-03-17","lastUpdate":"2021-03-17"},"enrollment":479,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Coronavirus","Acute Respiratory Infection","SARS-CoV Infection"],"interventions":[{"type":"DRUG","name":"Hydroxychloroquine","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Hydroxychlorquine","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"ORCHID is a multicenter, blinded, placebo-controlled, randomized clinical trial evaluating hydroxychloroquine for the treatment of adults hospitalized with COVID-19. Patients, treating clinicians, and study personnel will all be blinded to study group assignment.","primaryOutcome":{"measure":"COVID Outcomes Scale Score on Study Day 15 (14 Days After Randomization)","timeFrame":"Assessed on study day 15","effectByArm":[{"arm":"Hydroxychloroquine","deltaMin":6,"sd":null},{"arm":"Placebo","deltaMin":6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":40,"countries":["United States"]},"refs":{"pmids":["33165621","32492354"],"seeAlso":["http://petalnet.org"]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":242},"commonTop":["Multiple Liver Function Tests Abnormal","Prolonged QTc","Headache","Atrial Arrythmia","Nausea"]}}